BioSpace News Archive

The Hintermann Series H2 is a semi-constrained, total ankle replacement prosthesis developed by a world-renowned foot and ankle surgeon based in Switzerland.

The company recently began a program to determine the three-dimensional structure of the NR2F6 nuclear receptor.

CelGro, for a range of dental bone and soft tissue regeneration procedures, can now be marketed and sold within the European Union (EU).

Net revenue1 growth of 14.0% in Q3, with same store sales of 7%. YTD growth of 18.0%, SSS of 11%.

This statement is provided for shareholders who are United States persons for purposes of the U.S. Internal Revenue Code of 1986, as amended and the related United States Treasury regulations.

Under the terms of the agreement, ArcherDX will use their patented Anchored Multiplex PCR technology combined with the Illumina MiSeqDx sequencing system and Archer Analysis bioinformatics software to develop the CDx.

Nov. 8, 2017 13:00 UTC Velesco Pharma Awarded Subcontract to Develop and Manufacture Clinical Supplies for a New Treatment for Beta-Thalassemia PLYMOUTH, Mich.--( BUSINESS WIRE )-- Velesco Pharmaceutical Services, Inc. , has announced the award of a subcontract for analytical method development, manufacturing clinical supplies, and testing the stability of an investigational drug for the treatment for Beta-Thalassemia, a bloo

CytRx today announced financial results for the quarter ended September 30, 2017, and provided an overview of recent accomplishments and plans.

Tepha announced today recent developments and R & D initiatives in the field of regenerative medicine scaffolds for the repair or replacement of compromised human tissue.

Dr. Panagakos will lead the U.S. clinical science team activities related to the development of clinical studies, publications, and continuing to strengthen relationships with regional and national professional associations aligned with regenerative dentistry.